导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.37% | 3660/4773 |
| 近一周 | -3.02% | 4492/5465 |
| 近一月 | -2.50% | 1713/5421 |
| 近一季 | -5.50% | 2089/5231 |
| 近半年 | -15.87% | 4122/4920 |
| 近一年 | -8.45% | 3312/4394 |
| 近两年 | 19.82% | 2656/2954 |
| 近三年 | -7.55% | 2008/2253 |
| 成立以来 | -13.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.07% 1075/4961 |
-6.57% 3716/5312 |
- - |
- - |
| 2025 | 2.91% 3159/4813 |
-6.44% 3355/3635 |
1.79% 2139/4076 |
8.10% 3419/4524 |
-0.03% 2311/4813 |
| 2024 | 11.75% 1299/3463 |
3.81% 509/2808 |
-0.33% 739/3014 |
8.08% 2774/3129 |
-0.07% 1307/3463 |
| 2023 | -7.68% 936/2656 |
12.28% 306/2280 |
0.78% 276/2385 |
-6.70% 1497/2515 |
-12.55% 2460/2655 |
| 2022 | -12.36% 278/2207 |
-4.41% 164/1919 |
1.43% 1478/2016 |
-12.20% 666/2113 |
2.95% 798/2208 |
| 2021 | 22.27% 152/1822 |
6.71% 90/1255 |
-3.77% 1252/1330 |
19.20% 56/1466 |
-0.11% 1201/1822 |
| 2020 | -8.83% 989/1250 |
-6.79% 510/1028 |
-5.10% 1046/1067 |
6.61% 823/1164 |
-3.31% 1127/1184 |
| 2019 | -3.54% 814/1092 |
16.38% 671/754 |
-11.04% 757/804 |
-7.34% 820/850 |
0.55% 882/918 |
| 2018 | -30.51% 470/834 |
- - |
- - |
- - |
-8.95% 111/691 |
| 2017 | -8.04% 524/714 |
- - |
- - |
- - |
- - |
| 2016 | 20.85% 1/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证基建工程指数(LOF)A VS. 长安沪深300非周期A(740101) |